"More than half" of Medicare Part D drugs are generics

19 February 2007

The USA-based Generic Pharmaceutical Association (GPhA) has welcomed the news that the majority of all drug prescriptions issued under the Medicare Part D benefit for senior citizens, are dispensed as generic drugs, according to the Centers for Medicare and Medicaid Services (CMS).

Kathleen Jaeger, the GPhA's president said that the "CMS deserves enormous credit for educating Medicare Part D beneficiaries about the benefits of using safe, effective and affordable generic medicines. Thanks to our efforts, nearly 60% of all Part D prescriptions dispensed are generics."

Ms Jaeger noted that the development of generic biopharmaceuticals would provide considerable benefit to US patients. An estimate published by the Pharmaceutical Care Management Association suggests that $14.0 billion over 10 years could be saved from the Medicare Part B program alone.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight